+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cluster Headache Treatment Market 2019-2025

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129738
Cluster Headache Treatment Market Size, Share, & Trend Analysis Report, By Treatment (Drug (Triptans, Octreotide, Dihydroergotamine, and Others) and Device), and Forecast Period 2019-2025.

The global cluster headache treatment market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include an increasing number of cases of cluster headache disorder coupled with technological advancement and increasing development in the health care sector. The global cluster headache treatment market is segmented based on drugs and devices. Based on drug type, the market is classified into triptans, octreotide, dihydroergotamine and others. Geographically, the market is classified into North America, Europe, Asia-Pacific, and the Rest of the World.

North America has witnessed optimistic growth in the market in 2018 owing to the significant rise in cluster headache diseases coupled with the major market leaders operating in the region. Asia-Pacific is estimated to witness significant growth during the forecast period owing to the increasing number of geriatric population in the region. Additionally, the rising number of hospitals and private clinics is further strengthening the market growth in the region.

The major players in the global cluster headache treatment market include AstraZeneca PLC, Aurobindo Pharma, Ltd., Dr. Reddy's Laboratories, Ltd., ElectroCore Medical LLC, Eli Lilly and Company, Fresenius Kabi Pharmaceuticals Holding, Inc., GlaxoSmithKline PLC, Merck KGaA, Mylan N.V., Novartis AG, and Ranbaxy Laboratories, Ltd. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe. In September 2018, ElectrCore started serving its episodic cluster treatment with GammaCore sapphire therapy in the US to expand its geographical presence as the US has the huge market for cluster headache treatment with around more than 0.35 million people suffering from cluster headache provides a huge opportunity for the company as well as the market to grow.

Research Methodology

The market study of the global cluster headache treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for drugs manufacturers, medical device manufacturers, suppliers and distributors, and government agencies for overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

The Report Covers:
  • Comprehensive research methodologies of the global cluster headache treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cluster headache treatment market.
  • Insights about market determinants which are stimulating the global spinal implants market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. GlaxoSmithKline PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. ElectroCore Medical LLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Mylan N.V. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. AstraZeneca PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Novartis AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Cluster Headache Treatment Market by Treatment
5.1.1. Drugs Triptans Octreotide Dihydroergotamine Others (Local Anesthetics)
5.1.2. Devices
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AstraZeneca PLC
7.2. Aurobindo Pharma, Ltd.
7.3. Autonomic Technologies, Inc.
7.4. Dr. Reddy's Laboratories, Ltd.
7.5. ElectroCore Medical LLC
7.6. Eli Lilly and Company
7.7. Fresenius Kabi Pharmaceuticals Holding, Inc.
7.8. GlaxoSmithKline PLC
7.9. Janssen Pharmaceuticals, Inc.
7.10. LGM Pharma, LLC
7.11. Merck KGaA
7.12. Mylan N.V.
7.13. Novartis AG
7.14. Par Pharmaceutical Companies, Inc.
7.15. Ranbaxy Laboratories, Ltd.
7.16. Sagent Pharmaceuticals, Inc.
7.17. Sun Pharmaceutical Industries Ltd.
7.18. Teva Pharmaceutical Industries Ltd.
7.19. TrioxBio Inc.
7.20. Winston Pharmaceuticals Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca PLC
  • Aurobindo Pharma, Ltd.
  • Autonomic Technologies, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • ElectroCore Medical LLC
  • Eli Lilly and Company
  • Fresenius Kabi Pharmaceuticals Holding, Inc.
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • LGM Pharma, LLC
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Par Pharmaceutical Companies, Inc.
  • Ranbaxy Laboratories, Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TrioxBio Inc.
  • Winston Pharmaceuticals Inc.